Despite the relatively wide product range in Russian pharmacies there isa shortage of cheaper drugs, says Benjamin Moonblit, health care and pharmaceutical projects director at InterMatrix. This is believed to be due mainly to pharmacists' reluctance to handle cheaper drugs, but also reflects problems in the Russian health care system.
Health insurance provides a 50% drug discount for certain people, while the handicapped, decorated war veterans, people involved in the Chernobyl nuclear plant cleanup and others are entitled to free drugs. But in practice, apart from in Moscow and a few larger cities, free drugs are in short supply, and are frequently "misappropriated" by operators who then reportedly overcharge the state and regional authorities for them.
Another feature is the wide gap between the ex-factory and pharmacy prices, attributed by local experts to inadequate marketing and distribution. Russian drug imports are handled by several intermediate agents and there is frequent marking-up to establish "assets to offset contingencies." The government is supposedly monitoring drug prices, and limits on markups have been imposed, in theory, in all provinces except the Samara region. The markup on drugs in Moscow, for example, must not exceed 50% of the ex-factory price. But in practice, efforts to contain soaring drug prices have been unsuccessful and importers have bypassed restrictions. The trade is lucrative.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze